IMMP
HEALTHCAREImmutep Ltd
$0.44-0.02 (-3.74%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IMMP Today?
No stock-specific AI insight has been generated for IMMP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.29$3.32
$0.44
Fundamentals
Market Cap$65M
P/E Ratio—
EPS$-0.43
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume758K
Avg Volume (10D)—
Shares Outstanding147.4M
IMMP News
31 articles- IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire·May 8, 2026
- Immutep Receives Nasdaq Notice of Bid Price DeficiencyYahoo Finance·Apr 30, 2026
- Immutep Quarterly Activities Report Q3 FY26Yahoo Finance·Apr 30, 2026
- IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 27, 2026
- Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual MeetingYahoo Finance·Apr 22, 2026
- Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue SarcomaYahoo Finance·Apr 21, 2026
- IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 19, 2026
- IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 15, 2026
- Sector Update: Health Care Stocks Decline Late AfternoonYahoo Finance·Apr 15, 2026
- Sector Update: Health Care Stocks Lower in Afternoon TradingYahoo Finance·Apr 15, 2026
- Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue SarcomaGlobeNewswire Inc.·Apr 15, 2026
- CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 11, 2026
- IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 11, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMPGlobeNewswire Inc.·Apr 7, 2026
- Immutep Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 5, 2026
- IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 3, 2026
- POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - POMGlobeNewswire Inc.·Mar 30, 2026
- IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Mar 30, 2026
- IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Mar 25, 2026
- Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune DiseasesYahoo Finance·Mar 19, 2026
- Adobe downgraded, Nio upgraded: Wall Street’s top analyst callsYahoo Finance·Mar 14, 2026
- Immutep’s LAG-3 hopes take a hit on Phase III NSCLC terminationClinicaltrialsarena·Mar 13, 2026
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility AnalysisYahoo Finance·Mar 13, 2026
- Evotec, Vistagen lay off staff; Immutep shares collapse on study failureBiopharmadive·Mar 13, 2026
- 3 ASX Penny Stocks With Market Caps Under A$600MYahoo Finance·Feb 18, 2026
- Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 50% of the companyYahoo Finance·Feb 9, 2026
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLCYahoo Finance·Feb 6, 2026
- Immutep Quarterly Activities Report Q2 FY26Yahoo Finance·Jan 29, 2026
- Dr. Reddy's Laboratories Q3 Earnings Call HighlightsMarketbeat·Jan 21, 2026
- ASX Penny Stocks Spotlight: Immutep And Two More To ConsiderYahoo Finance·Jan 13, 2026
- Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I StudyYahoo Finance·Dec 22, 2025
All 31 articles loaded
Price Data
Open$0.45
Previous Close$0.46
Day High$0.45
Day Low$0.44
52 Week High$3.32
52 Week Low$0.29
52-Week Range
$0.29$3.32
$0.44
Fundamentals
Market Cap$65M
P/E Ratio—
EPS$-0.43
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume758K
Avg Volume (10D)—
Shares Outstanding147.4M
About Immutep Ltd
Immutep Limited, a biotechnology company, is dedicated to the research and development of pharmaceutical candidates. The company is headquartered in Sydney, Australia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—